Xenon Pharmaceuticals (NASDAQ:XENE) Director Gillian Cannon Sells 1,190 Shares of Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Gillian Cannon sold 1,190 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $63,236.60. Following the completion of the transaction, the director owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. This represents a 44.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Xenon Pharmaceuticals Trading Down 1.0%

NASDAQ:XENE opened at $51.21 on Tuesday. Xenon Pharmaceuticals Inc. has a 12 month low of $30.00 and a 12 month high of $63.95. The stock has a 50 day moving average of $55.74 and a two-hundred day moving average of $48.68. The firm has a market cap of $4.95 billion, a P/E ratio of -10.90 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, hitting the consensus estimate of ($1.17). During the same period in the previous year, the business earned ($0.83) EPS. On average, research analysts forecast that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on XENE shares. Guggenheim reiterated a “buy” rating and set a $90.00 price objective on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Deutsche Bank Aktiengesellschaft boosted their price objective on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Royal Bank Of Canada boosted their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Jefferies Financial Group set a $100.00 price objective on Xenon Pharmaceuticals in a research note on Monday, March 9th. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $69.00 price objective on shares of Xenon Pharmaceuticals in a research note on Sunday, May 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $77.20.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in XENE. Danske Bank A S acquired a new position in shares of Xenon Pharmaceuticals during the 3rd quarter worth approximately $32,000. Blue Trust Inc. boosted its holdings in shares of Xenon Pharmaceuticals by 2,560.7% during the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 717 shares during the last quarter. Kestra Advisory Services LLC acquired a new position in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $33,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Xenon Pharmaceuticals during the 3rd quarter worth approximately $39,000. Finally, Osaic Holdings Inc. boosted its holdings in shares of Xenon Pharmaceuticals by 541.4% during the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,034 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.